CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,495,607
- in 10 filings, $79.5M under 10b5-1 plans
Net −$79,495,607. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-01-31 | Clague Laura Chief Financial Officer | Grant or award · Performance-based restricted stock units | +10,000 | 10,000 | ||
| 2020-01-31 | Dube Eric M Chief Executive Officer | Grant or award | +35,000 | 77,500 | ||
| 2020-01-31 | Dube Eric M Chief Executive Officer | Grant or award · Employee stock option (right to buy) | +300,000 | 300,000 | ||
| 2020-01-31 | Dube Eric M Chief Executive Officer | Grant or award · Performance-based restricted stock units | +35,000 | 35,000 | ||
| 2020-01-31 | Dube Eric M Chief Executive Officer | Grant or award · Performance-based restricted stock units | +30,000 | 30,000 | ||
| 2020-01-08 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −750 | $15.14 | $11K | 18,008 |
| 2020-01-08 | Dube Eric M Chief Executive Officer | Sale | −3,750 | $15.14 | $57K | 42,500 |
| 2020-01-07 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −750 | $13.94 | $10K | 18,758 |
| 2020-01-07 | Dube Eric M Chief Executive Officer | Sale | −3,750 | $13.94 | $52K | 46,250 |
| 2019-11-29 | ASELAGE STEVE Director | Sale | −5,000 | $13.91 | $70K | 250,966 |
| 2019-10-01 | Heerma Peter Chief Commercial Officer | Grant or award | +35,000 | 35,000 | ||
| 2019-10-01 | Heerma Peter Chief Commercial Officer | Grant or award · Employee stock option (right to buy) | +100,000 | 100,000 | ||
| 2019-07-31 | Rosenberg Noah L. Chief Medical Officer | Sale | −1,250 | $20.07 | $25K | 13,500 |
| 2019-07-30 | Rosenberg Noah L. Chief Medical Officer | Sale | −1,250 | $19.82 | $25K | 14,750 |
| 2019-05-16 | McFarlane Neil F. Chief Operating Officer | Sale | −984 | $18.71 | $18K | 26,988 |
| 2019-05-16 | Clague Laura Chief Financial Officer | Sale | −1,250 | $18.71 | $23K | 13,500 |
| 2019-05-15 | McFarlane Neil F. Chief Operating Officer | Sale | −984 | $17.78 | $17K | 27,972 |
| 2019-05-15 | Clague Laura Chief Financial Officer | Sale | −1,250 | $17.78 | $22K | 14,750 |
| 2019-05-15 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −812 | $17.76 | $14K | 18,185 |
| 2019-05-15 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −525 | $17.71 | $9K | 19,508 |
Page 45 of 51 · 1,020 trades